Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26108604 | 1.00 | GSR (0.36) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL16862530 | 0.90 | GSR (0.38) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL16862531 | 0.90 | GSR (0.38) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL2211497 | 0.87 | CPB2 (0.42) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL1039473 | 0.87 | CPB2 (0.42) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL7416589 | 0.87 | CPB2 (0.42) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL11117299 | 0.85 | GSR (0.38) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| Ethylenediamine SCHEMBL17669759 | 0.85 | CPB2 (0.41) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| Ethylenediamine SCHEMBL17669758 | 0.85 | CPB2 (0.41) | GSRCPB2RNPEPTPSAB1TPSD1 | |
| SCHEMBL1022347 | 0.82 | CPB2 (0.40) | GSRCPB2RNPEPTPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | GSR 3408/4885CPB2 985/4885RNPEP 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.